
Shares of healthcare giant Novo Nordisk (NVO) have been on an absolute tear in the last year, rising 68.9% in the last 12 months. Valued at a market cap of $579 billion, Novo Nordisk has returned over 7,800% to shareholders, after adjusting for dividends, since March 2004.
Novo Nordisk is engaged in the research and development, manufacture, and distribution of healthcare products in Europe and other international markets. It has two primary business segments: Diabetes and Obesity Care, and Rare Diseases.